

CDC Admits It Never Monitored VAERS for COVID Vaccine Safety Signals

In response to a Freedom of Information Request submitted by Children's Health Defense, the Centers for Disease Control and Prevention last week admitted it never analyzed the Vaccine Adverse Event Reporting System for safety signals for COVID-19 vaccines.

By Josh Guetzkow, Ph.D.

Miss a day, miss a lot. [Subscribe to The Defender's Top News of the Day. It's free.](#)

In a stunning development, the Centers for Disease Control and Prevention (CDC) last week admitted — despite assurances to the contrary — the agency never analyzed the Vaccine Adverse Event Reporting System (VAERS) for safety signals for [COVID-19](#) vaccines.

The admission was revealed in response to a Freedom of Information Act (FOIA) request submitted by [Children's Health Defense](#) (CHD).

In September 2021, I published [an article](#) in [The Defender](#) in which I used the CDC's published methodology to analyze VAERS for safety signals from COVID-19 vaccines.

The signals were loud and clear, leading me to wonder “why is nobody listening?”

Instead, I should have asked, “Is anybody even looking for them?”

After that article was published, I urged [CHD's legal team](#) to submit a FOIA request to the CDC about its [VAERS](#) monitoring activities.

Since CDC officials [stated publicly](#) that “[COVID-19](#) vaccine safety monitoring is the most robust in U.S. history,” I had assumed that at the very least, CDC officials were monitoring VAERS using the methods they described in [a briefing document](#) posted on the CDC website in January 2021 (and [updated](#) in February 2022, with minor changes).

I was wrong.

The lynchpin of their safety monitoring was to mine VAERS data for safety signals by calculating what are known as proportional reporting ratios (PRR's).

This is a method of comparing the proportion of different types of adverse events reported for a new vaccine to the proportion of those events reported for an older, established vaccine.

If the new vaccine shows a significantly higher reporting rate of a particular [adverse event](#) relative to the old one, it counts as a safety signal that should then trigger a more thorough investigation.

The briefing document states, “CDC will perform PRR data mining on a weekly basis or as needed.”

2.3.1 Proportional Reporting Ratio (PRR)

CDC will perform PRR data mining on a weekly basis or as needed. PRRs compare the proportion of a specific AE following a specific vaccine versus the proportion of the same AE following receipt of another vaccine (see equation below Table 4). A safety signal is defined as a PRR of at least 2, chi-squared statistic of at least 4, and 3 or more cases of the AE following receipt of the specific vaccine of interest.

CDC will apply appropriate comparator vaccines (e.g., adjuvanted vaccines like Shingrix and/or Flud for adjuvanted COVID-19 vaccines) and adjust for severity and age distributions where applicable.

And yet, in the agency's response to the FOIA request, it wrote that "no PRRs were conducted by CDC. Furthermore, data mining is outside of the agency's purview."

The agency suggested contacting the [U.S. Food and Drug Administration \(FDA\)](#), which was supposed to perform a different type of data mining, according to the briefing document.



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

June 16, 2022

Divyanshi Dwivedi
Children's Health Defense
Via email: divyanshi.dwivedi@childrenshealthdefense.org

Dear Ms. Dwivedi:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of May 9, 2022, assigned #22-01479-FOIA (copy attached).

We located 104 pages of responsive records for Item 1 of your request. After a careful review of these pages, no information was withheld from release.

In regards to Item 2, program staff within the Immunization and Safety Office inform me that no PRRs were conducted by CDC. Furthermore, data mining is outside of the agency's purview; staff suggest you inquire with FDA.

In regards to Item 3, program staff inform me that, while VAERS has conducted "signal assessment" as described in section 2.5 (i.e. assessed that a causal association exists between the vaccine and both TTS and myocarditis), that assessment involved no formal records. Documentation for this exists in ACIP presentations and publications in the biomedical literature. For your convenience, a listing of those publications is included.

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6246.

Sincerely,

A handwritten signature in black ink, appearing to read "Roger Andoh".

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

22-01479-FOIA

CDC officials repeatedly claimed they have not seen safety signals in VAERS.

2.5 Signal assessment

Signal detection can occur in VAERS surveillance through FDA empirical Bayesian data mining, through CDC PRR data mining, and through descriptive analysis. When a potential signal is detected, ISO VAERS staff shall take a series of steps to assess the potential signal. Steps may include, but are not limited to:

- Assess if the potential signal merits further investigation (e.g., expected AEs might not warrant further analysis)
- Consult with FDA colleagues to coordinate response
- Perform quality checks on data management and data analysis that led to signal detection
- Individual report review to:
 - Confirm the accuracy of MedDRA coding
 - Confirm the AE outcome and apply a standardized case definition if appropriate
 - Confirm onset interval to assess biological plausibility
 - Assess for other risk factors that might contribute to the AE
 - Assess the clinical seriousness
- Perform comparative analysis with other vaccines (e.g., compare frequencies and proportions with influenza vaccine)
- Analyze reporting rates and compare reporting rates with other vaccines or background rates

If, after an initial assessment, VAERS investigators determine a signal warrants further investigation, the VAERS team lead will notify ISO leadership and develop a coordinated response plan. Any appropriate investigation will be conducted in collaboration with FDA. FDA will share with CDC reports of possible concern based on the data mining results and assess product-specific or lot safety as appropriate. ISO leadership will be responsible for notifying NCIRD and the CDC COVID-19 Vaccine Task Force (VTF) in a timely manner.

For example, on April 27, 2021, [CDC Director Dr. Rochelle Walensky](#) stated the CDC did not see any signals related to [heart inflammation](#).

But a PRR calculation I did using the number of myo/pericarditis reports listed in the first table produced by the CDC obtained via the FOIA request reveals clear and unambiguous safety signals relative to the comparator vaccines mentioned in the briefing document (i.e., flu vaccines, FLUAD and Shingrix).

The table is dated April 2, 2021, almost four weeks before she made those remarks.

In fact, among the 15 adverse events for adults included in that week's tabulations, PRRs I calculated also show loud-and-clear safety signals for acute myocardial infarction, anaphylaxis, appendicitis, Bell's palsy, coagulopathy, multisystem inflammatory syndrome in adults (MIS-A), stroke and death.

The actual monitoring the CDC did diverges from the one promised in the briefing document in other ways.

For example, the CDC never created tables of the top 25 adverse events reported in the previous week, tables comparing different vaccine manufacturers, or tables of auto-immune diseases.

And it only began monitoring in early April 2021, even though reports from COVID-19 vaccines had been flooding VAERS since mid-December of the previous year.

To be clear, VAERS is not the only database the CDC uses to monitor COVID-19 vaccine safety.

For example, the CDC sponsored several studies of COVID-19 safety using the [Vaccine Safety Datalink \(VSD\)](#), which is comprised of millions of medical records from HMO's across several states.

Those studies do not raise many safety concerns. However, they make many questionable methodological choices.

To give one example, a [major safety study](#) based on VSD data published in September 2021, in "JAMA," compares adverse event rates that occur within 1-21 days of vaccination to the rate of occurrence from 22 to 42 days after vaccination.

It makes no comparison between vaccinated and unvaccinated individuals, or before vaccination versus after in the same individuals.

Moreover, the VSD is far from infallible, having failed initially to detect the increase in [myocarditis rates](#).

In contrast, although calculating PRR's is a blunt pharmacovigilance tool and [far from perfect](#), it nevertheless has the advantage of being straightforward and difficult to manipulate with statistical sleight of hand.

PRRs are one of the oldest, most basic and most well-established tools of pharmacovigilance. The calculations are so straightforward that the CDC automated it several [years ago](#), so it could have been done at the press of a button.

It simply beggars belief that the CDC failed to do this simple calculation. Even now, [a paper published](#) by CDC staff in March on the safety of the mRNA COVID-19 vaccines remains purely descriptive with no PRR calculation.

Meanwhile, [a study](#) published by a researcher not affiliated with the CDC in February in "Frontiers in Public Health" analyzes VAERS and [EudraVigilance](#) data using a method similar to PRRs, revealing clear and concerning safety signals.

And while it is true that VAERS is not the only database the CDC can use to monitor COVID-19 vaccine safety, it is of critical importance because it can reveal signals much faster than any other method — if anybody cares to look for them.

It remains to be seen if the [FDA](#) was properly monitoring VAERS. That will be the subject of a future FOIA request.

But even if it was, it doesn't change the fact that the CDC completely failed in its promise to monitor VAERS for safety signals.

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children's Health Defense.

SUGGEST A CORRECTION



Josh Guetzkow, Ph.D.

Josh Guetzkow is a senior lecturer in the Department of Sociology & Anthropology and the Institute of Criminology at the Hebrew University of Jerusalem.

[Sign up](#) for free news and updates from Robert F. Kennedy, Jr. and the Children's Health Defense. CHD is planning many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured. Your [support](#) is essential to CHD's successful mission.

[Republishing Guidelines](#)

